Exicure, Inc.
XCURHealthcare|Biotechnology|US
$0.95
+0.06 (+6.71%)
DCF Value
$0.35
Cash / Share
$0.27
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03684785 Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | P1P2 | Terminated | 57 | RCT, Open-label | Cavrotolimod, Pembrolizumab, Cemiplimab, Cavrotolimod |
| NCT03086278 A Study of AST-008 in Healthy Subjects | Healthy Volunteer Study | P1 | Completed | 16 | Open-label | AST-008 |